## **REMARKS**

Claim 56 has been amended to clarify the unified nature of the indications myelosupression, mucositis and peripheral neuropathy. As was clear from the claims as originally filed, for example claim 38, all of these listed indications are actually side effects of treatment with anti-neoplastic agents. The subject to be treated must be undergoing antineoplastic treatment as required by the claim. Thus, these indications all have a common orgin as side effects and thus it appears to applicants they could be examined in the same application.

Applicants would appreciate reconsideration of the restriction requirement to the extent that Groups III, V and VII have been restricted.

## CONCLUSION

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing docket no. 204372000901. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: April 11, 2002

Registration No. (29,959)

Morrison & Foerster LLP 3811 Valley Centre Drive

Suite 500

San Diego, California 92130-2332

Telephone: (858) 720-5112 Facsimile: (858) 720-5125

## **EXHIBIT A. - VERSION WITH MARKINGS TO SHOW CHANGES MADE**

56. (Amended) A method to ameliorate [myelosupression, mucositis or peripheral neuropathy] a side effect of anti-neoplasia treatment in a subject, wherein said side effect is myelosupression, mucositis or peripheral neuropathy, which subject has been treated with [a neoplastic] an anti-neoplastia agent, which method comprises administering to said subject a pharmaceutical composition comprising MTP-PE encapsulated in multilamellar liposomes.